Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones.

作者: Felice Iasevoli , Sara Giordano , Raffaele Balletta , Gianmarco Latte , Maria Vittoria Formato

DOI: 10.1016/J.PNPBP.2015.08.010

关键词:

摘要: The aim of this work was to compare achievements in milestones community functioning highly disabling psychiatric conditions, including treatment resistant schizophrenia (TRS), (responsive antipsychotics), bipolar disorder, and anxiety/depressive diseases. Also, we investigated the predictors outcomes across several domains. Among consecutive patients screened, 188 met inclusion criteria 118 ultimately entered study. Diagnosis TRS made by stringent criteria, historic perspective evaluations excluding potential confounding factors. Achievements functional everyday living were recorded. Performances discrete cognitive tasks assessed. Positive Negative Syndrome Scale, Personal Social Performance Drug Attitude Inventory-10, Quality Life Enjoyment Satisfaction Questionnaire administered. showed highest impairment among diagnostic groups. found have more severe psychopathology, impaired functioning, poorer psychosocial adjustment compared all other In whole sample, main group (with diagnosis associated with worst functioning) milestones. psychotic patients, however, clinical psychopathological variables. These results may support hypothesis that represents a separate subtype, its own neurobiology, psychopathology course. Our identify modifiable be addressed prevent disability.

参考文章(78)
Dawn I. Velligan, Philip D. Harvey, International assessment of functional skills in people with schizophrenia Innovations in clinical neuroscience. ,vol. 8, pp. 15- 18 ,(2011)
Kane Jm, Treatment-resistant schizophrenic patients. The Journal of Clinical Psychiatry. pp. 35- 40 ,(1996)
Jean-Pierre Lindenmayer, Treatment refractory schizophrenia. Psychiatric Quarterly. ,vol. 71, pp. 373- 384 ,(2000) , 10.1023/A:1004640408501
Vladimir Lerner, High-dose olanzapine for treatment-refractory schizophrenia. Clinical Neuropharmacology. ,vol. 26, pp. 58- 61 ,(2003) , 10.1097/00002826-200303000-00003
J Frank, M Lang, S H Witt, J Strohmaier, D Rujescu, S Cichon, F Degenhardt, M M Nöthen, D A Collier, S Ripke, D Naber, M Rietschel, Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients Molecular Psychiatry. ,vol. 20, pp. 150- 151 ,(2015) , 10.1038/MP.2014.56
Andrea de Bartolomeis, Raffaele Balletta, Sara Giordano, Elisabetta Filomena Buonaguro, Gianmarco Latte, Felice Iasevoli, Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses. Psychiatry Research-neuroimaging. ,vol. 210, pp. 387- 395 ,(2013) , 10.1016/J.PSYCHRES.2013.06.042
Martin T. Strassnig, Tenko Raykov, Cedric O'Gorman, Christopher R. Bowie, Samir Sabbag, Dante Durand, Thomas L. Patterson, Amy Pinkham, David L. Penn, Philip D. Harvey, Determinants of different aspects of everyday outcome in schizophrenia: The roles of negative symptoms, cognition, and functional capacity. Schizophrenia Research. ,vol. 165, pp. 76- 82 ,(2015) , 10.1016/J.SCHRES.2015.03.033
Alessandro Rossi, Anna Bagalà, Vincenzo Del Curatolo, Francesco Scapati, Micaela Maria Bernareggi, Maria Grazia Giustra, , Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder† Human Psychopharmacology-clinical and Experimental. ,vol. 24, pp. 574- 583 ,(2009) , 10.1002/HUP.1067